Business
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has acquired an exclusive license with Visara, Inc. ("Visara"), a subsidiary of NovaBridge Biosciences (formerly known as I-Mab, and is a company listed on the Nasdaq Global Market trading under the symbol "NBP"), to secure an exclusive license to develop, manufacture and
About this update from Everest Medicines Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries.","length":179,"tagName":"p"}]},{"val":[{"type":"text","content":"Under the assigned exclusive license, Everest Medicines will make an upfront payment of US$7 million (equivalent to approximately RMB49.7 million) and reimburse up to RMB24.0 million for prior expenses; and pay up to US$89.0 million (equivalent to approximately RMB632.0 million) in potential milestones; plus tied royalties on net sales.","length":338,"tagName":"p"}]},{"val":[{"type":"text","content":"VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2 that is more potent and could potentially provide more durable treatment benefits than existing treatments for patients with wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. VIS-101 is anticipated to be Phase 3-ready in 2026.","length":339,"tagName":"p"}]},{"val":[{"type":"text","content":"By leveraging Everest Medicines' strong clinical development and commercialization platform, both parties will collaborate closely to efficiently advance the clinical development and commercialization of VIS-101 in China and across Asia, accelerating the delivery of this potentially best-in-class ophthalmology innovative therapy to patients.","length":347,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1203,"olType":false},{"type":"text","content":"SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has acquired an exclusive license with Visara, Inc. ("Visara"), a subsidiary of NovaBridge Biosciences (formerly known as I-Mab, and is a company listed on the Nasdaq Global Market trading under the symbol "NBP"), to secure an exclusive license to develop, manufacture and commercialize VIS-101, in Greater China, Singapore, South Korea and certain Southeast Asian countries.","length":688,"tagName":"p"},{"type":"text","content":"Under the assigned exclusive license, Everest Medicines will make an ...